SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-20-022893
Filing Date
2020-08-19
Accepted
2020-08-19 16:21:28
Documents
47
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q rasp-20200630.htm   iXBRL 10-Q 848576
7 EXHIBITS 31.1 ex311_1.htm EX-31.1 16612
8 EXHIBITS 32.1 ex321_2.htm EX-32.1 5091
  Complete submission text file 0001213900-20-022893.txt   4841682

Data Files

Seq Description Document Type Size
2 DEFINITION rasp-20200630_def.xml EX-101.DEF 264983
3 PRESENTATION rasp-20200630_pre.xml EX-101.PRE 417408
4 CALCULATION rasp-20200630_cal.xml EX-101.CAL 47600
5 LABEL rasp-20200630_lab.xml EX-101.LAB 836785
6 SCHEMA rasp-20200630.xsd EX-101.SCH 53710
9 EXTRACTED XBRL INSTANCE DOCUMENT rasp-20200630_htm.xml XML 532772
Mailing Address 420 LEXINGTON AVENUE SUITE 2525 NEW YORK NY 10170
Business Address 420 LEXINGTON AVENUE SUITE 2525 NEW YORK NY 10170 646-396-4087
Rasna Therapeutics Inc. (Filer) CIK: 0001582249 (see all company filings)

IRS No.: 392080103 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 10-Q | Act: 34 | File No.: 333-191083 | Film No.: 201117307
SIC: 2834 Pharmaceutical Preparations